Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04114981 · ClinicalTrials.gov registry record · Phase 3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

A Phase 3 study of Metastatic Malignant Neoplasm in the Brain, sponsored by Alliance for Clinical Trials in Oncology.

Active
Registry status
Phase 3
Development phase
242
Enrollment target
20
Study locations

NCT04114981 is a Phase 3 study of Metastatic Malignant Neoplasm in the Brain that is active but no longer recruiting, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 242 participants, above the 82-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (195% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04114981, a Phase 3 study of Metastatic Malignant Neoplasm in the Brain, is active but no longer recruiting, sponsored by Alliance for Clinical Trials in Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
242 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.

Interventions

  • OTHER Questionnaire Administration
  • PROCEDURE Quality-of-Life Assessment
  • RADIATION Single Fraction Stereotactic Radiosurgery
  • RADIATION Fractionated Stereotactic Radiosurgery

Study Locations (20)

Arizona

  • Banner MD Anderson Cancer Center - Gilbert
  • Banner Thunderbird Medical Center - Glendale
  • Banner-University Medical Center Phoenix - Phoenix
  • Mayo Clinic Hospital in Arizona - Phoenix
  • Mayo Clinic in Arizona - Scottsdale
  • University of Arizona Cancer Center-North Campus - Tucson

California

  • UC San Diego Moores Cancer Center - La Jolla
  • Los Angeles County-USC Medical Center - Los Angeles
  • USC / Norris Comprehensive Cancer Center - Los Angeles
  • Epic Care Cyberknife Center - Walnut Creek

Arkansas

  • Mercy Hospital Fort Smith - Fort Smith
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro

Colorado

  • University of Colorado Hospital - Aurora
  • UCHealth Memorial Hospital Central - Colorado Springs

Delaware

  • Helen F Graham Cancer Center - Newark
  • Beebe Health Campus - Rehoboth Beach

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Alaska

  • Anchorage Radiation Therapy Center - Anchorage

Connecticut

  • Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 242 participants
Start Date 2019-11-19
Est. Completion 2028-03
Phase Phase 3

What the Registry Record Tells You About NCT04114981

The ClinicalTrials.gov registry entry for NCT04114981 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (195% higher). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.

NCT04114981 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Arizona, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT04114981 about?

NCT04114981 is a clinical study titled "Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease". This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosur...

What is the current status of trial NCT04114981?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2019-11-19. Estimated completion is 2028-03.

What conditions does trial NCT04114981 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain.

What interventions are being tested in trial NCT04114981?

The interventions under investigation include: Questionnaire Administration (OTHER), Quality-of-Life Assessment (PROCEDURE), Single Fraction Stereotactic Radiosurgery (RADIATION), Fractionated Stereotactic Radiosurgery (RADIATION).

Who is sponsoring clinical trial NCT04114981?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04114981 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Neoplasm in the Brain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.